Early start: a cost-beneficial perinatal substance abuse program

Area of Science:

• Public Health
• Health Economics
• Obstetrics

Background:

• Substance use during pregnancy poses significant risks to maternal and infant health.
• Integrated prenatal interventions aim to mitigate these risks and improve outcomes.
• Quantifying the economic impact of such interventions is crucial for healthcare policy.

Purpose of the Study:

• To perform a cost-benefit analysis of the Early Start program, an integrated prenatal intervention designed to reduce substance use in pregnant women.
• To compare healthcare costs associated with maternal and infant care across different intervention and control groups.

Main Methods:

• A retrospective cohort study involving 49,261 women utilizing prenatal substance abuse screening and urine toxicology.
• Comparison of four groups: Early Start intervention, screened and assessed without follow-up, screened positive only, and negative screen controls.
• Maternal, neonatal, and pediatric healthcare costs (prenatal through 1 year postpartum/pediatric care) were adjusted to 2009 dollars and controlled for demographic and prenatal care variables.

Main Results:

• Women screened positive only incurred significantly higher maternal ($10,869), infant ($16,943), and overall ($27,812) costs compared to all other groups (P<.001).
• The Early Start program demonstrated significantly lower adjusted mean total costs for both mothers and infants compared to the screened-assessed and control groups.
• Annual implementation costs for Early Start were $670,600, with a net cost benefit averaging $5,946,741 per year.

Conclusions:

• The Early Start program is a cost-beneficial intervention for managing substance use in pregnancy.
• The intervention leads to improved maternal-infant outcomes and substantial overall cost reductions.
• The economic benefits of Early Start significantly outweigh its implementation costs, supporting its widespread adoption.